Transforming vaccine efficacy in respiratory disease
Madison WI USA
Joined August 2012
- Tweets224
- Following110
- Followers290
- Likes86
FluGen's M2SR in Lancet ID today showing superior resposne when combined with Fluzone High Dose in older adults versus Fluzone High Dose alone (thelancet.com/journals/lanin…) This could be a big improvement in preventing flu... bit.ly/3S3gvMC
And while you're at it- take a look at Healthcare Business Today to read more about M2SR's potential
healthcarebusinesstoday.com/…
On the latest episode of the @BioBossPodcast, FluGen Founder and CEO Paul Radspinner discusses his career journey and the science behind FluGen’s vaccine program. To hear the full podcast, head to the BioBoss website: bioboss.buzzsprout.com/
We're excited to announce completion of first cohort in age de-escalation clinical trial of M2SR flu vaccine candidate in pediatric subjects ages 6 Months to 17 Years! flugen.com/news/
More confirmation that mucosal immunity is critical cnn.com/2022/07/18/health/mu…
FluGen, Inc. retweeted
.@UWMadison investigators are eligible to apply for @DeptofDefense funding to catalyze innovative medical solutions for military applications and rapidly migrate those technologies out of the lab and into use. #WisconsinInnovates engineering.wisc.edu/blog/wi…
FluGen, Inc. retweeted
.@FluGenInc announced the dosing of its first subject, in an unprecedented study of older adults ages 65-85 years, to evaluate the effectiveness of its intranasal #flu #vaccine. ow.ly/hN7g50JJa8c #clinicaltrials
We are pleased to announce the first subject has been dosed in phase 1b clinical trial of our intranasal M2SR Flu Vaccine, co-administered with High Dose Vaccine, in older adults!
See flugen.com/news/ for full announcement
FluGen, Inc. retweeted
[ALA Client News] #Naobios delivers @flugeninc’s M2SR #influenza #vaccine candidate for upcoming clinical trials
@FluSpinner
ala.com/projects/naobios-del…
FluGen to Present at 40th Annual J.P. Morgan Healthcare Conference 1/12/22 @ 4:30 PM E.T.
Visit flugen.com/for-investors/ for more info!
FluGen management will be presenting at Baird's 2021 Global Healthcare Conference tonight @ 5:30 PM ET watch it here: kvgo.com/baird-2021-global-h…
Journal of Infectious Diseases publishes positive data from our Ph.2 human challenge study of our M2SR #flu #vaccine candidate, showing protection against highly drifted strain of H3N2 flu [prn.to/3xeng0J]
We are happy to announce that @DeptofDefense has awarded us funding to conduct a safety & immunogenicity study to asses our M2SR #flu #vaccine candidate and the current standard of care high dose vaccine in adults 65 and older prn.to/2UbMcs2
Watch FluGen President & CEO Paul Radspinner speak at the @Jefferies 2021 Virtual Healthcare Conference
wsw.com/webcast/jeff174/flu/…
We are pleased to launch the first #flu #vaccine study of M2SR in adults up to 85. Funded by @NIH, our study will assess safety, tolerability, and immunological response in people vulnerable to flu. prn.to/2TcY3Wd
FluGen, Inc. retweeted
ICYMI, watch my interview with @FluGenInc CEO Paul Radspinner. We chatted about FluGen’s approach to developing a Covid-19 vaccine, what the biggest challenges are, and what vaccine-makers need to do to ensure patients they are safe and effective. bizjournals.com/milwaukee/in…
Reminder: you can still register for tomorrow's virtual fireside chat to hear from our CEO Paul Radspinner
Mark your calendars! I'll be hosting a fireside chat with @FluGenInc CEO Paul Radpsinner on Sept. 29 to discuss the company's progress on developing a Covid-19 vaccine. FluGen was named one of @WisconsinInno's #CrisisInnovators last month. Register here: register.gotowebinar.com/reg…
FluGen, Inc. retweeted
In this episode of #ExecutiveCorner, we'll be taking a closer look with Andy Skibo from @FluGenInc & @RfwrightLSL from Life Science Leader at what factors are important for #risk mitigation and #leadership in the #biomanufacturing industry.
Listen now ➡️ biomanamerica.com/podcast/